Yedida Y Bogachkov PhD,  —

Team PHenomenal Hope’s research fund, the PHenomenal Impact Fund for Global PH Research, will help finance pulmonary hypertension (PH) research for the fourth consecutive year. “Team PHenomenal Hope [Team PH] actively seeks ways to improve the quality of life for those with Pulmonary Hypertension by building community, providing…

A new study highlights the predictive utility of hypochromic erythrocytes — red blood cells that have decreased levels of hemoglobin (the oxygen carrier) — in patients with pulmonary arterial hypertension (PAH). The increased presence of these erythrocytes was shown to be an independent predictor of both mortality and shorter…

Adults with pulmonary arterial hypertension (PAH) or chronic thromboembolic pulmonary hypertension (CTEPH) who have trouble breathing at rest or with light activity may benefit from a procedure called respiratory rate modulation, a pilot, single-center study shows. The three-month procedure also led to lower symptom severity and decreased respiratory…

Circulating endostatin, a protein that inhibits new blood vessel formation, appears to correlate well with mortality and disease severity in people with pulmonary arterial hypertension (PAH) in a large, observational study. Blood levels of endostatin show a “clear potential … as a robust prognostic biomarker in PAH” and could…

Children undergoing high-dose chemotherapy and hematopoietic stem cell transplant (HSCT) to treat their cancer should be screened for pulmonary arterial hypertension (PAH), according to a case report of two young patients at a Pennsylvania hospital. Its authors noted that other reports also suggested “possible links” between such treatments and PAH…

Opsynvi, a fixed-dose oral combination of macitentan and tadalafil, was approved by Health Canada for the long-term treatment of pulmonary arterial hypertension (PAH). It is for use by patients on stable doses of its two active compounds: macitentan (sold as Opsumit) at 10 mg and tadalafil (sold as Adcirca) at 40 mg. Marketed…